GlassScriptPhysician profile
Jill R Stanton
NPI 1710060058
$8,716.47
in general payments reported to CMS, 2019-2025
49 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,761 · 2020: $1,727 · 2021: $3,797 · 2022: $178 · 2023: $336 · 2024: $426 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,343.72 | 2021 | |
| Novo Nordisk INC | $940.26 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $646.84 | 2019-2025 | |
| Abbvie INC. | $579.36 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $503.69 | 2019-2021 | |
| Abbott Laboratories | $479.52 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Glaxosmithkline, LLC. | $415.46 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Eisai INC. | $361.02 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $271.03 | 2019-2021 | |
| Lilly USA, LLC | $262.59 | 2019-2025 | Zepbound, Mounjaro |
| Allergan, INC. | $260.84 | 2019-2020 | |
| Dexcom, INC. | $257.73 | 2024-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $257.69 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $209.34 | 2019-2021 | |
| Amgen INC. | $196.36 | 2019-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Stanton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.